Most recent articles by:
Pavlos Giorkas
Pavlos Giorkas is a blogger and content creator with a passion for crypto, health, consumer tech and money management. He's been dealing with cryptocurrency since 2013 but didn't take action until 3 years later on 2016. On Bitnewsbot he covers the latest news in the crypto space.
News
MetaMask Rolls Out Version 4.9.0 With Slew Of Updates
The most recent version of the blockchain Dapp browser extension comes with various new features.In an August 6 announcement, the team behind MetaMask unveiled...
News
Tezos Class Action Moves Forward After Judge Denies Motion to Dismiss
Arthur and Kathleen Breitman and the Tezos Foundation are being sued by Tezos "contributors."On August 7, the United States District Court of the Northern...
News
London Gallery To Hold Cryptocurrency Art Exhibition
The House of Fine Art is making its collection available for purchase using cryptocurrency.According to local daily newspaper The London Evening Standard, the House...
News
Cryptocurrency Regulation, From A(ntigua) to Z(ambia) – ThirtyK
The nation’s Securities and Exchange Commission in early August proposed rules governing ICOs that presume all tokens are regulated securities unless proven otherwise by...
News
SEC’s Postponement Of Bitcoin ETF Decision May Not Keep Prices Down
Investors need to learn patience.The US Security and Exchange Commission (SEC) has decided to postpone a decision regarding a bitcoin-backed exchange traded fund (ETF),...
News
If Crypto Can Go Mainstream It’s BAKKT to the Future – ThirtyK
Is cryptocurrency now ready to go mainstream?
Friday’s announcement that the parent company of the New York Stock Exchange was joining forces with Microsoft, Starbucks...
News
New York Names Cynthia Hanawalt As New Investor Protection Bureau Chief
A new leader of the agency charged with enforcing the state’s securities laws has been chosen, and she seems cautious of cryptocurrency.On Tuesday, the...
News
Embleema Tests Blockchain for Patient Health Care Data – ThirtyK
As pharmaceuticals become more personalized to individuals’ specific genomes, drug developers must rely on medical data gathered outside clinical trials, known as real world...
